Replies to post #243738 on Innovation Pharmaceuticals Inc (IPIX)

[frrol]

The inclusion of IBD in licensing negotiations was a very welcome bit of news. Frankly it was a head scratcher why it was 'omitted' in the first announcement (which just mentioned OM), since both are GI tract anti-inflammatory indications and a licensee should naturally want both.
Looking out for that deal announcement.

[Empiricst1]

Farell, could not agree more. The IBD-UC-Crohn's continuum is huge, but I am still bothered that we have small data, great pictures but no PH 2b. I know BP could purchase early, but that seems just a bit too far out for a good deal. IPIX needs to fund its IBD 2b, then watch it grow. So Leo has to loosen up the Brilacidin for ABSSSI or the Prurisol (if it has good results) to get some funding. We can't just keep our cake and somehow expect it to all come out fine.